Scarica l'app Stockscreener
6.85
2.35%
-0.17
Precedente Chiudi:
$7.02
Aprire:
$7.03
Volume 24 ore:
45,607
Relative Volume:
0.33
Capitalizzazione di mercato:
$313.50M
Reddito:
$239.40M
Utile/perdita netta:
$104.44M
Rapporto P/E:
2.3142
EPS:
2.96
Flusso di cassa netto:
$-18.50M
1 W Prestazione:
-3.72%
1M Prestazione:
-10.97%
6M Prestazione:
-60.63%
1 anno Prestazione:
-51.62%
Intervallo 1D:
$6.85
$7.075
Intervallo di 1 settimana:
$6.80
$7.20
Portata 52W:
$6.80
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Nome
Entrada Therapeutics Inc
Settore
Industria
Telefono
857-305-1825
Indirizzo
ONE DESIGN CENTER PLACE, BOSTON
Confronta TRDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
6.85 | 313.50M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.71 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.34 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
558.35 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.13 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-01-05 | Iniziato | Oppenheimer | Outperform |
| 2023-04-03 | Iniziato | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
(TRDA) Long Term Investment Analysis - news.stocktradersdaily.com
Harbor Capital Advisors Inc. Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Wall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to Sell - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 21,594 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Millennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting - TipRanks
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Holdings Raised by Bank of America Corp DE - Defense World
Transcript : Entrada Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Mackenzie Financial Corp Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
How the (TRDA) price action is used to our Advantage - news.stocktradersdaily.com
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLC - Defense World
Entrada Therapeutics expands board with new director By Investing.com - Investing.com South Africa
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewswire
Entrada Therapeutics expands board with new director - Investing.com
Entrada Therapeutics (TRDA) Welcomes New Board Member | TRDA Stock News - GuruFocus
Entrada Therapeutics Appoints New Board Member - TipRanks
3,324 Shares in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Bought by BNP Paribas Financial Markets - Defense World
Ameriprise Financial Inc. Buys 2,517 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics - TipRanks
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Entrada Therapeutics Awards Nearly 24,000 RSUs in Latest Employee Compensation Plan - Stock Titan
Deutsche Bank AG Grows Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics to start DMD trial in Q3 2025 By Investing.com - Investing.com South Africa
Entrada Therapeutics (TRDA) Gains EU Approval for Advanced Clinical Study | TRDA Stock News - GuruFocus
Entrada Therapeutics to start DMD trial in Q3 2025 - Investing.com
Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025 - Nasdaq
Breakthrough DMD Treatment Gets EU Green Light: Entrada's Novel Exon 45 Therapy Heads to Clinical Trials - Stock Titan
HC Wainwright Brokers Boost Earnings Estimates for TRDA - Defense World
Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace
Q2 Earnings Forecast for TRDA Issued By HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World
Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics (TRDA) Receives 'Buy' Rating Reiteration by HC Wainwright | TRDA Stock News - GuruFocus
Tower Research Capital LLC TRC Cuts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
(TRDA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Roth Capital Issues Negative Outlook for TRDA Earnings - Defense World
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital - TipRanks
Entrada Therapeutics (TRDA) Sees Price Target Adjustment Amid Cl - GuruFocus
Roth Capital Adjusts Price Target for Entrada Therapeutics (TRDA - GuruFocus
Roth Capital Adjusts Price Target for Entrada Therapeutics (TRDA) | TRDA Stock News - GuruFocus
Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results - Yahoo Finance
Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating - TipRanks
Entrada Therapeutics reports Q1 EPS (42c), consensus (77c) - TipRanks
Entrada Therapeutics earnings beat by $0.31, revenue fell short of estimates - Investing.com
Entrada Therapeutics (TRDA) Reports Strong Q1 Revenue and Advances Duchenne Programs | TRDA Stock News - GuruFocus
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Entrada Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
First Trust Advisors LP Sells 7,800 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
MetLife Investment Management LLC Acquires 1,731 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics Inc Azioni (TRDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Entrada Therapeutics Inc Azioni (TRDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| WENTWORTH KORY JAMES | Chief Financial Officer |
Mar 17 '25 |
Sale |
10.67 |
1,784 |
19,035 |
109,536 |
1.37%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):